Unilabs Sweden Launches Subtle Medical’s AI-powered Imaging Technology to Further Bolstering Patient Care
Unilabs, the leading diagnostic services provider, announced a partnership with Subtle Medical, a healthcare technology company using artificial intelligence for faster and higher quality MRI, to further improve the quality and efficiency of their MRI imaging. The solution, which will first be rolled out in Sweden, will boost Unilabs’ MRI programme to provide industry-leading productivity and an even more superior patient experience.
“Unilabs is dedicated to investing in healthcare innovation for the benefit of all of our patients. Having safe, clinically validated, state-of-the-art tools for improved image acquisition is key in the practice of modern radiology,” said Dr Thomas Lindahl, Medical Director Unilabs Sweden. “The SubtleMR solution will assist our radiologists in performing high-quality imaging more efficiently.”
SubtleMR™ is an AI-powered software that improves image quality from upwards of 60% faster scan times. The software has been clinically validated in multiple peer-reviewed journals showing clinical quality and integrity across diverse sites, scanners, and patients.
SubtleMR™ enables centres to optimise workflows while improving the patient’s imaging journey by reducing the amount of time spent in the scanner.
“We could not be more pleased that Unilabs has adopted SubtleMR,” said Josh Gurewitz, Chief Commercial Officer for Subtle Medical. “Our unique technology not only supports a better patient experience from less time in the imaging suite but also increases operational workflow efficiencies that allow Unilabs to boost their already efficient imaging programme. We look forward to a long partnership with Unilabs.”
To hear Dr. Lindahl speak on behalf of the new partnership and meet with the Subtle Medical team, attend the Satellite Symposia hosted by Subtle Medical at ECR in Vienna, Austria on Friday, July 15th at 12:30. RSVP here.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more